Follow us...

 

Search News Archives

Channels

News

 

 

View Channel

Laboratory Products

 

 

View Channel

Special Offers and Promotions

 

Microscopy | Image Analysis

 

 

View Channel

Separation Science

 

 

View Channel

Coronavirus (COVID-19)

 

 

View Channel

Research & Case Studies

 

 

View Channel

Brochures & Literature

 

 

View Channel

 

Conferences | Events

Cell-line Derived Controls for Diagnostic Assay Development

publication date: Nov 2, 2017
 | 
author/source: AMSBIO

Cell

AMSBIO announce the addition of mutation cell line Formalin-Fixed Paraffin-Embedded (FFPE) samples and isolated genomic DNA (gDNA) controls to its extensive range of cell line reference standards.

In both routine clinical use and diagnostic assay development, biologically-relevant positive and negative controls represent an invaluable resource. To ensure accuracy and reproducibility during IVD assay development and established diagnostic tests, reference standards for genomic DNA analysis and Immunohistochemistry (IHC) assays are an essential tool. However reliable sources of reference material for rarer genetic profiles remain a constant challenge.

IsoMax™ reference standards have been accurately engineered to model the genetics of specific patient populations in vitro. These unique new reference standards can be directly incorporated into sample processing workflows for assay optimization, evaluation of sensitivity and specificity as well as monitoring the impact of workflow changes on downstream analysis.

Building on the CellMax™ range of more than 50 well-known cancer cell line FFPE controls, IsoMax™ reference standards provide a renewable source of control material for recognized mutations in cancer markers.  Based on CRISPR/Cas9 isogenic cell lines, a wide range of mutations are offered from target genes, including EGFR, KRAS, BRAF, and PIK3CA.

Available in multiple formats, including FFPE blocks, slides, scrolls, and isolate gDNA, IsoMax™ and CellMax™ standards provide an inexhaustible supply of consistent positive and negative controls.

Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products and services for research and development in the medical, nutrition, cosmetics and energy industries. AMSBIO can draw upon in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion and proliferation. Widely acknowledged as an expert in cell culture, AMSBIO partners with clients in tailoring cell systems to enhance organoid and spheroid type screening outcomes from a technological and cost-effective perspective. Custom services include stable cell line production, CRISPR/Cas9 Genome Editing, lentivirus and adenovirus production, large scale protein production and a comprehensive portfolio of antibody services.


more about AMSBIO


more news from AMSBIO


 

 

 


If you have not logged into the website then please enter your details below.



 

Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin

 

Request your free copies HERE

 

 

 

Popular this Month...

Our Top 10 most popular articles this month

 

Today's Picks...

 

 


 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.


 

Media Partners